# Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US.

*biotech · news · 2026-04-22 · The Manila Times*

## Key points

- The FDA has extended the Sarclisa subcutaneous target action date to July 23, 2026.
- If approved, Sarclisa would be the first anticancer treatment delivered via on-body injector.
- The European CHMP recommended Sarclisa subcutaneous for all indications of its IV formulation in March 2026.
- Sarclisa subcutaneous is being reviewed for use with all currently approved multiple myeloma regimens.

**Companies:** Sanofi
**Countries:** France, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/22/tmt-newswire/globenewswire/press-release-sanofi-provides-update-on-the-regulatory-submission-for-sarclisa-subcutaneous-in-the-us/2325666)

---

Canonical: https://newsio.io/n/c8bc9bb4-b46d-4498-a4f3-8e993284f78f/sanofi-provides-update-on-the-regulatory-submission-for-sarclisa-subcutaneous-in
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works